Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy
Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy
复制标题
DOI：
10.1111/j.1442-2050.2010.01119.x
复制
发表时间：
2011-04-01
影响因子：
2.6
通讯作者：
Ogawa, J. -I.
中科院分区：
文献类型：
--
作者：
Maruyama, K.;Motoyama, S.;Ogawa, J. -I.
我们探讨了食管鳞癌术后放化疗对淋巴结复发和血行转移的治疗效果。2001年至2006年，216例胸段食管鳞状细胞癌患者接受了根治性食管切除术。其中23例淋巴结复发者行放化疗（50.0-68.8戈伊）。此外，5例患者在远处器官中出现孤立性复发，并接受了放化疗（50.0-60.0戈伊）。我们分析了复发性食管癌放射治疗的结果。23例淋巴结复发患者行放化疗后1、2、5年生存率分别为52%、31%、24%，中位生存时间为13个月。在远处器官复发肿瘤的5例患者中，放化疗在2例患者中产生了完全反应，1例患者中产生了部分反应，2例患者中产生了稳定的疾病，有效率为60%（完全反应+部分反应）。放化疗对食管鳞癌淋巴结复发患者有良好的预后作用。对于全身化疗被证明无效的情况，针对远处器官转移性肿瘤的放化疗可能是治疗的选择。
P>We investigated the effectiveness of chemoradiotherapy for the treatment of lymph node recurrence and hematogenous metastasis after esophagectomy for esophageal squamous cell carcinoma. Between 2001 and 2006, 216 patients with thoracic esophageal squamous cell carcinoma had curative esophagectomy. Of those, 23 with lymph node recurrence received chemoradiotherapy (50.0-68.8 Gy). In addition, five patients had isolated recurrences in a distant organ and received chemoradiotherapy (50.0-60.0 Gy). We analyzed outcomes from the radiotherapy for recurrent esophageal cancer. The 1-, 2-, and 5-year survival rates after recurrence for the 23 patients whose lymph node recurrence was treated with chemoradiotherapy were 52, 31, and 24%, respectively, and the median survival time was 13 months. Among the five patients with recurrent tumors in a distant organ, chemoradiotherapy produced a complete response in two patients, a partial response in one patient, and stable disease in two patients, giving an effectiveness rate of 60% (complete response + partial response). Chemoradiotherapy has a beneficial prognostic effect in patients with lymph node recurrence of esophageal squamous cell carcinoma. Chemoradiotherapy for a metastatic tumor in a distant organ may be the treatment of choice in cases where systemic chemotherapy has proven ineffective.